Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Chin J Integr Med ; 26(5): 388-392, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-30623343

RESUMEN

The development of Chinese medicine and Western medicine andrology is based on different social background and academic systems, either Chinese medicine or Western medicine andrology has their limitations, therefore, integration of Chinese and Western medicine (ICWM) andrology is in a great need. After more than 30 years of development, andrology has made great achievements in the construction of specialized academic association, holding academic conferences and publication of academic monographs, and the research progress on this field is mainly in the combination of disease and syndrome, microdifferentiation of symptoms and signs and basic research development. However, the comprehensive theoretic system of ICWM andrology has not yet established, and the related studies are still on the primary stage. In the future studies, great efforts still need to be made to expand the methods for the investigation of ICWM, and make innovations in the field of andrology.


Asunto(s)
Andrología/tendencias , Medicina Tradicional China/tendencias , Publicaciones Periódicas como Asunto , Proyectos de Investigación , Humanos , Masculino
2.
Zhongguo Zhong Yao Za Zhi ; 44(12): 2580-2587, 2019 Jun.
Artículo en Chino | MEDLINE | ID: mdl-31359727

RESUMEN

Panax japonicus is a traditional Chinese medicine,and its principle components have shown certain pharmacological activities for cell damage,aging and cell apoptosis. In order to clarify the pharmacological mechanism and involved metabolic pathways of P. japonicas,the gene expression of Tetrahymena thermophila under P. japonicus treatment was analyzed through high-throughput transcriptome sequencing in this study. Based on the transcriptome analysis,3 544 differentially expressed genes were identified in control group,of which 1 945 genes showed up-regulated expression and 1 599 genes showed down-regulated expression. Under P. japonicas treatment in the experiment group,3 312 differentially expressed genes were screened,of which 1 `493 genes showed up-regulated expression and 1 819 genes showed down-regulated expression. GO enrichment analysis indicated that in control group,the genes in the cells in a series of fundamental biological process were down-regulated,such as DNA replication and protein synthesis; while the signal transduction process and fatty acids oxidizing process were enriched. Whereas in the experiment group,down-regulated genes were mainly enriched in oxidation-reduction,cofactor metabolic process and vitamin metabolic process; up-regulated genes were enriched in signal transduction process and protein modification process. In the analysis using KEGG database,cell cycle pathway was enhanced and autophagy pathway was inhibited under the condition of P. japonicas treatment. Real-time quantitative polymerase chain reaction( RT-qPCR) was used to detect the expression differences between 6 up-regulated and 4 down-regulated genes in related metabolic pathways. The RT-q PCR results and RNA-Seq data were highly correlated and consistent with each other. This study could provide important direction and basis for further study on the mechanism of cell growth regulation with the treatment of P. japonica.


Asunto(s)
Panax/química , Plantas Medicinales/química , Tetrahymena thermophila/efectos de los fármacos , Tetrahymena thermophila/genética , Transcriptoma , Expresión Génica , Perfilación de la Expresión Génica , Redes y Vías Metabólicas
3.
Huan Jing Ke Xue ; 38(6): 2546-2552, 2017 Jun 08.
Artículo en Chino | MEDLINE | ID: mdl-29965376

RESUMEN

An in-situ paddy experiment was conducted to study the remedying effects of a combined amendment(calcium carbonate+diatomite+ferric sulfate) on Cd bioavailability in soil and Cd accumulation in rice for spring and autumn rice planted in a certain Cd contaminated paddy soil in Beishan Town, Changsha, Hunan Province. The results showed that:Application of the combined amendment significantly increased soil pH and CEC values in both cultivated seasons, but decreased soil OM contents for the spring rice. During the experiment, the contents of TCLP-extractable Cd and CaCl2-extractable Cd in soil were reduced by 18.0%-33.0% and 5.4%-57.9%, respectively. The Cd contents in brown rice, husk, leave and root for the spring rice decreased by 29.6%-56.1%, 52.1%-54.0%, 18.1%-80.7% and 24.4%-41.6%, respectively, due to application of the combined amendment. There were significant differences in Cd transport capacity between spring rice and autumn rice, and the transportation of soil Cd in autumn rice was smoother than that in spring rice. For the autumn rice, the effects of the combined amendment were not significant(P>0.05), except that the Cd content in husk increased a little after applying 2 g·kg-1 of the combined amendment. Significant positive correlations were found between the Cd contents in brown rice and the contents of TCLP-extractable Cd or CaCl2-extractable Cd in soil. Application of the combined amendment effectively inhibited Cd uptake by rice root and reduced Cd content in brown rice for the spring rice; however, these remedying effects were significantly weakened for the autumn rice due to loss of the combined amendment with the movement of irrigation water in the spring season. Therefore, we suggest that supplement of the combined amendment is necessary between two rice cultivated seasons.


Asunto(s)
Cadmio/aislamiento & purificación , Carbonato de Calcio/química , Tierra de Diatomeas/química , Compuestos Férricos/química , Oryza , Contaminantes del Suelo/aislamiento & purificación , Estaciones del Año , Suelo
4.
Zhonghua Nan Ke Xue ; 23(2): 164-168, 2017 Feb.
Artículo en Chino | MEDLINE | ID: mdl-29658256

RESUMEN

OBJECTIVE: To study the safety and efficacy of Bushen Daozhuo Granules (BDG) in the treatment of type Ⅲ prostatitis. METHODS: This multicenter randomized controlled clinical trial included 478 patients with type Ⅲ prostatitis, 290 in the trial group and 188 as controls, the former treated with BDG at 200 ml bid and the latter with tamsulosin hydrochloride sustainedrelease capsules at 0.2 mg qd, both for 4 weeks. Before treatment, after 4 weeks of medication, and at 4 weeks after drug withdrawal, we obtained the NIH Chronic Prostatitis Symptom Index (NIHCPSI) scores and compared the safety and effectiveness rate between the two groups of patients. RESULTS: Compared with the baseline, the NIHCPSI score was markedly decreased in the control group after 4 weeks of medication (21.42 ± 4.02 vs 15.67 ± 3.65, P < 0.05) but showed no statistically significant difference from that at 4 weeks after drug withdrawal (19.03 ± 3.86) (P>0.05), while the NIHCPSI score in the trial group was remarkably lower than the baseline both after 4 weeks of medication and at 4 weeks after drug withdrawal (10.92 ± 2.06 and 12.91 ± 2.64 vs 21.58 ± 3.67, P < 0.05). The trial group exhibited both a higher rate of total effectiveness and safety than the control (P < 0.05). CONCLUSIONS: BDG is safe and effective for the treatment of type Ⅲ prostatitis.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Prostatitis/tratamiento farmacológico , Agentes Urológicos/uso terapéutico , Cápsulas , Enfermedad Crónica , Preparaciones de Acción Retardada , Medicamentos Herbarios Chinos/efectos adversos , Humanos , Masculino , Prostatitis/patología , Sulfonamidas/efectos adversos , Sulfonamidas/uso terapéutico , Tamsulosina , Resultado del Tratamiento , Agentes Urológicos/efectos adversos
5.
Artículo en Inglés | MEDLINE | ID: mdl-27247607

RESUMEN

Background. This study is to explore the effect of corilagin on the proliferation and NF-κB signaling pathway in U251 glioblastoma cells and U251 glioblastoma stem-like cells. Methods. CD133 positive U251 glioblastoma cells were separated by immunomagnetic beads to isolate glioblastoma stem-like cells. U251 cells and stem-like cells were intervened by different corilagin concentrations (0, 25, 50, and 100 µg/mL) for 48 h, respectively. Cell morphology, cell counting kit-8 assay, flow cytometry, dual luciferase reporter assay, and a western blot were used to detect and analyze the cell proliferation and cell cycle and investigate the expression of IKBα protein in cytoplasm and NF-κB/p65 in nucleus. Results. Corilagin inhibited the cell proliferation of U251 cells and their stem-like cells and the inhibition role was stronger in U251 stem-like cells (P < 0.05). The cell cycle was arrested at G2/M phase in the U251 cells following corilagin intervention; the proportion of cells in G2/M phase increased as the concentration of corilagin increased (P < 0.05). The U251 stem-like cells were arrested at the S phase following treatment with corilagin; the proportion of cells in the S phase increased as the concentration of corilagin increased (P < 0.05). The ratio of dual luciferase activities of U251 stem-like cells was lower than that of U251 cells in the same corilagin concentration. With increasing concentrations of corilagin, the IKBα expression in cytoplasm of U251 cells and U251 stem-like cells was increased, but the p65 expression in nucleus of U251 cells and U251 stem-like cells was decreased (P < 0.05). Conclusion. Corilagin can inhibit the proliferation of glioblastoma cells and glioblastoma stem-like cells; the inhibition on glioblastoma stem-like cell proliferation is stronger than glioblastoma cells. This different result indicates that the effect of corilagin on U251 cells and U251 stem-like cells may have close relationships with mechanism of cell cycle and NF-κB signaling pathway; however, the real antitumor mechanism of corilagin is not yet clear and requires further study.

6.
Oncotarget ; 6(16): 14329-43, 2015 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-25869210

RESUMEN

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations are responsive to EGFR-tyrosine kinase inhibitor (EGFR-TKI). However, NSCLC patients with secondary somatic EGFR mutations are resistant to EGFR-TKI treatment. In this study, we investigated the effect of TG101348 (a JAK2 inhibitor) on the tumor growth of erlotinib-resistant NSCLC cells. Cell proliferation, apoptosis, gene expression and tumor growth were evaluated by diphenyltetrazolium bromide (MTT) assay, flow cytometry, terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) staining, Western Blot and a xenograft mouse model, respectively. Results showed that erlotinib had a stronger impact on the induction of apoptosis in erlotinib-sensitive PC-9 cells but had a weaker effect on erlotinib-resistant H1975 and H1650 cells than TG101348. TG101348 significantly enhanced the cytotoxicity of erlotinib to erlotinib-resistant NSCLC cells, stimulated erlotinib-induced apoptosis and downregulated the expressions of EGFR, p-EGFR, p-STAT3, Bcl-xL and survivin in erlotinib-resistant NSCLC cells. Moreover, the combined treatment of TG101348 and erlotinib induced apoptosis, inhibited the activation of p-EGFR and p-STAT3, and inhibited tumor growth of erlotinib-resistant NSCLC cells in vivo. Our results indicate that TG101348 is a potential adjuvant for NSCLC patients during erlotinib treatment.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Receptores ErbB/genética , Clorhidrato de Erlotinib/farmacología , Janus Quinasa 2/antagonistas & inhibidores , Neoplasias Pulmonares/tratamiento farmacológico , Pirrolidinas/farmacología , Sulfonamidas/farmacología , Animales , Apoptosis/efectos de los fármacos , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Carcinoma de Pulmón de Células no Pequeñas/patología , Proliferación Celular/efectos de los fármacos , Resistencia a Antineoplásicos , Sinergismo Farmacológico , Receptores ErbB/metabolismo , Femenino , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Ratones , Ratones Desnudos , Ensayos Antitumor por Modelo de Xenoinjerto
7.
Pharmacol Biochem Behav ; 111: 97-101, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24029464

RESUMEN

This study was designed to evaluate the anticonvulsant and sedative effects of paederosidic acid isolated from Paederia scandens (Lour.) Merrill. in mice and rats. In the present study, anticonvulsant activities of paederosidic acid were evaluated by maximal electroshock and pentylenetetrazole-induced seizures in male mice. Then, pentobarbital sodium-induced sleeping time and locomotor activity tests in mice were used to evaluate the sedative effects of paederosidic acid. Finally, the mechanism of paederosidic acid was explored by evaluating the contents of Glu and GABA in the brain, and Western blot was used to measure GAD65 expression in the mouse brain. Paederosidic acid (5, 10, 20, and 40 mg/kg, ip) had significant anticonvulsant and sedative effects. Moreover, paederosidic acid increased brain gamma-aminobutyric acid and decreased glutamic acid in the brain, and it up-regulated expressions of GAD 65. In conclusion, our results suggest that paederosidic acid may be a promising future therapeutic agent for treatment of epilepsy.


Asunto(s)
Anticonvulsivantes/farmacología , Glucósidos/farmacología , Compuestos Heterocíclicos con 2 Anillos/farmacología , Hipnóticos y Sedantes/farmacología , Extractos Vegetales/farmacología , Rubiaceae/química , Animales , Western Blotting , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Encéfalo/metabolismo , Glutamato Descarboxilasa/metabolismo , Ácido Glutámico/metabolismo , Masculino , Ratones , Ratones Endogámicos ICR , Ratas , Ratas Sprague-Dawley , Ácido gamma-Aminobutírico/metabolismo
8.
Zhonghua Nan Ke Xue ; 15(11): 1049-52, 2009 Nov.
Artículo en Chino | MEDLINE | ID: mdl-20218321

RESUMEN

OBJECTIVE: To evaluate the safety and efficacy of Qianliean Suppository in the treatment of chronic prostatitis of damp-heat and blood-stasis syndrome. METHODS: We conducted a randomized, single-blind, parallel-controlled, multi-centered clinical trial among 467 subjects, who were assigned to a trial group (n = 349) and a control group (n = 118), the former treated with Qianliean Suppository anally one pill per night for 28 days and the latter given Yejuhua Suppository in the same way. The efficacy was evaluated by the TCM syndrome, NIH-CPSI, main clinical symptoms and WBC count in EPS. RESULTS: After the treatment, the total rates of recovery, excellence and effectiveness for the TCM syndrome were 4.4%, 58.0% and 90.7% respectively in the trial group, significantly higher than 0.9%, 33.1% and 70.4% in the control group (P < 0.025). Remarkable decreases were observed in the NIH-CPSI total score and the scores on pain and discomfort, voiding symptoms and quality of life in the former group compared with the latter (P < 0.025). The trial group also showed a marked alleviation of such main chronic prostatitis symptoms as urgent micturition and perineal pain and discomfort (P < 0.05), as well as an obvious improvement (55.2%) of the WBC count in EPS as compared with 32.4% in the control group (P < 0.05). No serious adverse events occurred in either of the two groups (0.56% [2/349 ] vs 0.83% [1/118]). CONCLUSIONS: Qianliean Suppository is safe and effective for the treatment of chronic prostatitis of damp-heat and blood-stasis syndrome.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Fitoterapia , Prostatitis/tratamiento farmacológico , Adolescente , Adulto , Enfermedad Crónica , Medicamentos Herbarios Chinos/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Método Simple Ciego , Resultado del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA